Atossa Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of medicines in the areas of oncology and infectious diseases. The company's lead program is Endoxifen, an active metabolite of tamoxifen, which is in Phase II clinical trials to treat and prevent breast cancer. It is also developing AT-H201, an inhalation therapy to improve lung function in severely ill and hospitalized COVID-19 patients; AT-301, a proprietary drug candidate for nasal administration in patients diagnosed with COVID-19; and immunotherapy/chimeric antigen receptor therapy programs for the treatment of breast cancer. It has a research agreement with Dana-Farber Cancer Institute, Inc. to support research of cytokine-coated nanoparticles for the treatment of breast cancer. The company was formerly known as Atossa Genetics Inc. and changed its name to Atossa Therapeutics, Inc. in January 2020. Atossa Therapeutics, Inc. was founded in 2008 and is headquartered in Seattle, Washington.

Atossa Therapeutics, Inc.

Atossa Genetics Inc. (NASDAQ: ATOS) is developing locally-administered pharmaceuticals for pre-cancerous breast conditions and early stage breast cancer.

Aspire Capital Partners LLC

Keiretsu Forum Northwest

Excited to be participating in the Cantor Fitzgerald Healthcare conference today. Link to view the fireside chat with Dr. Quay is on the investor page of our website - https://lnkd.in/eJ7WFPZq

Looking forward to joining 14,000 biotech and pharma leaders in Boston next week.

Atossa to present poster at ASCO 2023 on Phase 2 EVANGELINE study - https://lnkd.in/eWZ2VVJf

NASDAQ:ATOS

Atossa Therapeutics Inc.

Last Close

1.41

24/09 20:00

Market Cap

150.91M

Beta: 1.17

Volume Today

603

Avg: 329.65K

PE Ratio

−3.72

PFCF: −5.28

People Not Available